Medication evidence profile
Vemurafenib
Clinical overview
Vemurafenib has public medication-list entries in Swe-ABS 2023 and GABS 2018. These are 2 separate source versions, each with its own evidence and definitions.
Source-specific scores
| Source | Score |
|---|---|
| JARS | Not listed |
| Yamada-ABS | Not listed |
| BAAS | Not listed |
| Swe-ABS | 0 |
| GABS | 0 |
| KABS | Not listed |
| CALS | Not listed |
How to read this: 0 means the source explicitly assigned zero. “Not listed” means the source did not provide a score for this medication. Scores from different scales are not averaged.
How to interpret the evidence
2 of 7 public source versions contain an explicit medication-list entry for Vemurafenib.
The available rows for Vemurafenib display the same numeric value. Agreement of the displayed numbers does not establish identical methods, clinical meaning or patient-level risk.
Swe-ABS 2023 and GABS 2018 explicitly record zero. Those recorded zeros remain different from a missing entry.
Source labels and provenance · 2 observations
- Swedish Anticholinergic Burden Scale 2023
Source label: Vemurafenib. Published value: 0.
Source version: SWE-ABS-2023
Source location: 12877_2023_4225_MOESM1_ESM.docx ST3 row 252
Observation: SWE_ABS_2023_R0377; rating state: published_zero. - German Anticholinergic Burden Score 2018
Source label: Vemurafenib. Published value: 0.
Source version: GABS-2018
Source location: 12877_2018_929_MOESM1_ESM.docx Table S3 row 350
Observation: GABS_2018_R0500; rating state: published_zero.
What this page does not establish
- No medication-list entry is available here from JARS 2025, Yamada-ABS 2023, BAAS 2019, KABS 2020 open validation supplement, and CALS 2022 Table 4. These gaps remain “Not listed”; no score is inferred from another source or from class membership.
- No route inference unless present in the source label.
- These source records do not estimate an individual’s probability of harm or establish whether to start, stop or change a medication. Ordinal source scores are not averaged into a UnifiedACB score.
References
- Rube T, Ecorcheville A, Londos E, Modig S, Johansson P. Development of the Swedish anticholinergic burden scale (Swe-ABS). BMC Geriatr. 2023;23(1):518. doi:10.1186/s12877-023-04225-1. Open source
- Kiesel EK, Hopf YM, Drey M. An anticholinergic burden score for German prescribers: score development. BMC Geriatr. 2018;18(1):239. doi:10.1186/s12877-018-0929-6. Open source
Ask a follow-up
Go to your medication comparison · How UnifiedACB handles disagreement
Ask about this medication
Medication context: Vemurafenib
Ask about this medication